Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
233.8 ^USD	-0.89%		-1.71%	+6.35%

Apr. 23	United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	MT
Apr. 23	United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
United Therapeutics Corporation announces an Equity Buyback for $1,000 million worth of its shares.	Mar. 25	CI
United Therapeutics Authorizes Accelerated $1 Billion Stock Buyback Through Citigroup	Mar. 25	MT
United Therapeutics Corporation authorizes a Buyback Plan.	Mar. 23	CI
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia	Feb. 21	MT
United Therapeutics Seeks Potential Acquisitions	Feb. 21	CI
United Therapeutics' Q4 Earnings, Revenue Rise	Feb. 21	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Posts Q4 Revenue $614.7M, vs. Street Est of $575.9M	Feb. 21	MT
United Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
North American Morning Briefing : Stocks Seen -2-	Feb. 13	DJ
US FDA Yutrepia Review Delay 'Yet Another Setback' For Liquidia, Wedbush Says	Jan. 25	MT
Liquidia Says United Therapeutics Filed for Dismissal of Certain Claims in Patent Infringement Litigation	Jan. 23	MT
Liquidia Shares Jump on US Court Win in Patent Dispute With United Therapeutics	Dec. 20	MT
United Therapeutics Corporation completed the acquisition of Miromatrix Medical Inc. from Gagnon Securities, LLC and others	Dec. 12	CI
United Therapeutics, Miromatrix Medical Report Successful Tender Offer	Dec. 12	MT
Eli Lilly and Company Grants United Therapeutics an Exclusive License	Nov. 29	CI
United Therapeutics' Q3 Earnings, Revenue Increase	Nov. 01	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q3 Revenue $609.4M, vs. Street Est of $585.8M	Nov. 01	MT
United Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Highlights

Filters